P1047: AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

P1047: AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

Bibliographic Details
Main Authors:	Andrea Duminuco, Adrian Mosquera-Orgueira, Antonella Nardo, Francesco DI Raimondo, Giuseppe Palumbo
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971084.17982.f2

Similar Items

AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
by: Andrea Duminuco, et al.
Published: (2023-10-01)

Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
by: Adrián Mosquera‐Orgueira, et al.
Published: (2024-03-01)

P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01)

P1028: MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX) MONOTHERAPY: PREDICTORS OF EARLY DISCONTINUATION AND DEATH ON TREATMENT. THE SHORT-TERM RUX PROGNOSTIC MODEL (STR-PM)
by: Francesca Palandri, et al.
Published: (2023-08-01)

Ruxolitinib as an emerging treatment in myelofibrosis
by: Emanuel RM, et al.
Published: (2013-03-01)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017-02-01)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
by: Tracy Clevenger, et al.
Published: (2023-08-01)

Comparison of Molecular International Prognostic Scoring System (M-IPSS) and Revised International Prognostic Scoring System (R-IPSS) in Thai patients with myelodysplastic neoplasms
by: Chantana Polprasert, et al.
Published: (2022-12-01)

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib
by: Claire Harrison
Published: (2015-04-01)

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome
by: Bruno Deltreggia Benites, et al.
Published: (2013-01-01)

Practical management of patients with myelofibrosis receiving ruxolitinib.
by: Harrison, C, et al.
Published: (2013)

Hemostasis in patients with primary myelofibrosis treated with ruxolitinib
by: O. G. Golovina, et al.
Published: (2024-11-01)

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
by: Naval Daver, et al.
Published: (2015-08-01)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012-03-01)

Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
by: Timothy Devos, et al.
Published: (2022-01-01)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
by: Giacomo Coltro, et al.
Published: (2023-04-01)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
by: Tiziano Barbui, et al.
Published: (2022-11-01)

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
by: Giuseppe A. Palumbo, et al.
Published: (2023-02-01)

P1010: RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME
by: F. Palandri, et al.
Published: (2022-06-01)

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib
by: Maheen Z. Abidi, et al.
Published: (2016-01-01)

Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung
by: Antoine El Kik, et al.
Published: (2024-01-01)

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib
by: Sunny Sandhu, et al.
Published: (2022-01-01)

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
by: David M. Ross, et al.
Published: (2021-01-01)

The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
by: Robert Peter Gale, et al.
Published: (2024-07-01)

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034
by: Haris Ali, et al.
Published: (2023-08-01)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
by: Massimo Breccia, et al.
Published: (2022-07-01)

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era
by: Yosuke Okada, et al.
Published: (2024-06-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
by: Bewersdorf JP, et al.
Published: (2019-12-01)

Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis
by: Anna Hirano, et al.
Published: (2017-01-01)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT-I AND -II TRIALS
by: Haifa Kathrin Al-Ali, et al.
Published: (2023-08-01)

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS
by: Chiara Elena, et al.
Published: (2011-01-01)

P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
by: P. Harrington, et al.
Published: (2022-06-01)

A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis
by: Claire Harrison, et al.
Published: (2022-08-01)

A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis
by: Tim Kong, et al.
Published: (2024-03-01)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
by: Vera Stoeva, et al.
Published: (2023-07-01)

Ruxolitinib for CALR-positive Myelofibrosis: A Case Report and Literature Review
by: GUO Huimei, et al.
Published: (2018-08-01)

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01)

The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
by: Butt, N, et al.
Published: (2019)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
by: Rosa Ayala, et al.
Published: (2023-08-01)